Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Payables (2021 - 2025)

Historic Payables for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $215.0 million.

  • Indivior Pharmaceuticals' Payables rose 12638.04% to $215.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 12638.04%. This contributed to the annual value of $216.0 million for FY2024, which is 909.09% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Payables stood at $215.0 million, which was up 12638.04% from $196.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Payables registered a high of $723.0 million during Q4 2021, and its lowest value of -$815.0 million during Q3 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' median Payables value was $189.5 million (recorded in 2025), while the average stood at -$119.2 million.
  • In the last 5 years, Indivior Pharmaceuticals' Payables plummeted by 6806.45% in 2023 and then surged by 12638.04% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Payables stood at $723.0 million in 2021, then decreased by 14.25% to $620.0 million in 2022, then crashed by 68.06% to $198.0 million in 2023, then grew by 9.09% to $216.0 million in 2024, then fell by 0.46% to $215.0 million in 2025.
  • Its Payables stands at $215.0 million for Q3 2025, versus $196.0 million for Q2 2025 and $183.0 million for Q1 2025.